PERTOFRANE Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Pertofrane, and when can generic versions of Pertofrane launch?

Pertofrane is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in PERTOFRANE is desipramine hydrochloride. There are nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the desipramine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pertofrane

A generic version of PERTOFRANE was approved as desipramine hydrochloride by ACTAVIS TOTOWA on June 5^th, 1987.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for PERTOFRANE?
What are the global sales for PERTOFRANE?
What is Average Wholesale Price for PERTOFRANE?

Summary for PERTOFRANE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	89
Clinical Trials:	3
Patent Applications:	1,509
Formulation / Manufacturing:	see details
DailyMed Link:	PERTOFRANE at DailyMed

Drug patent expirations by year for PERTOFRANE

Recent Clinical Trials for PERTOFRANE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Albert Einstein College of Medicine	N/A
National Cancer Institute (NCI)	N/A
Albert Einstein College of Medicine of Yeshiva University	N/A

See all PERTOFRANE clinical trials

US Patents and Regulatory Information for PERTOFRANE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	PERTOFRANE	desipramine hydrochloride	CAPSULE;ORAL	013621-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Sanofi Aventis Us	PERTOFRANE	desipramine hydrochloride	CAPSULE;ORAL	013621-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for PERTOFRANE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	PERTOFRANE	desipramine hydrochloride	CAPSULE;ORAL	013621-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Sanofi Aventis Us	PERTOFRANE	desipramine hydrochloride	CAPSULE;ORAL	013621-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Sanofi Aventis Us	PERTOFRANE	desipramine hydrochloride	CAPSULE;ORAL	013621-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Sanofi Aventis Us	PERTOFRANE	desipramine hydrochloride	CAPSULE;ORAL	013621-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for PERTOFRANE

See the table below for patents covering PERTOFRANE around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
France	1445454	Nouveaux dérivés d'iminodibenzyle et leur préparation	⤷ Sign Up
Spain	267641		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for PERTOFRANE

Recent Clinical Trials for PERTOFRANE

Make Better Decisions: Try a trial or see plans & pricing